Clinical Trial Update: Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) [Phase 1, Phase 2]

View source ↗

Summary

The ALTITUDE trial evaluating venetoclax, daratumumab, and dexamethasone for systemic light-chain (AL) amyloidosis with t(11;14) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis Light-chain

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Alfred Chung, MD | Conditions: AL Amyloidosis, Light Chain (AL) Amyloidosis | Phase 1, Phase 2 | Status: WITHDRAWN